15 Best Fast Growth Stocks To Buy Right Now

Page 5 of 15

11. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Holders: 50     

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is engineering solutions for rare diseases with science that is at the forefront of precision genetic medicine. In fiscal year 2024, total net product revenue was $638.2 million for the fourth quarter and $1.79 billion for the full year 2024, exceeding full-year guidance by over $100 million. In January, the company announced positive results from Part 2 of its Phase 3 EMBARK study for ELEVIDYS, the only approved gene therapy for Duchenne muscular dystrophy. MRI results from patients treated in Part 1 of the study showed minimal muscle pathology progression over two years, closely aligning with the functional benefits observed.

Page 5 of 15